Iptacopan in IgA Nephropathy — Final 24-Month Data

Data ReadoutpositiveIptacopanPositive

AI Analysis

Summary

Final 24-month efficacy and safety data for Iptacopan in IgA Nephropathy has been published in the New England Journal of Medicine, representing a major clinical milestone for the complement factor B inhibitor.

Clinical Trial Data

Outcome Details

Final 24-month data published in NEJM

Importance:7/10

Sentiment:

0.70

Clinical DataIgA NephropathyPeer-Reviewed PublicationNEJM

Related Companies

$SHWZ

Read the original article

Published by New England Journal of Medicine on March 29, 2026 5:10 AM

Read Original